Thanks maytepper. Personally I don't put much stock in an analyst who assigns a price target of $10 on IGI while maintaining a $37 price target on ANI. Especially when you look at the present profitability, the pipeline and profit margin, which will become more evident on Monday.
On the other hand, I appreciate his update on the Teva product experiencing a shortage.
A better barometer on the value is how much ANI and IGI had to give up of their company to raise $1 during the pubic offering both companies issued this year.
For every dollar raised during most recent public offerings, IGI had to give up 30% more of their company to raise the same amount of cash. This leads me to believe that those in the know have assessed ANI as being 30% more valuable than IGI.
If Oppenheimer's Rohit Vanjani were being objective in his assessment of ANI and he stands by his $10 price target placed on IGI, then he should have given ANI a price target of $60. Of course this would have been counter productive to those accumulating and/or bringing down their price per share.
JMHO
News 
Market Data 
Discover 
